16:40 EDT Ascendis Pharma up 6% at $106 after Q2 results, SKYTROFA revenue outlook raise
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ASND:
- Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
- New Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with Hypoparathyroidism
- Ascendis Pharma Reports Second Quarter 2023 Financial Results
- Options Volatility and Implied Earnings Moves Today, September 05, 2023
- Options Volatility and Implied Earnings Moves This Week, September 05 – September 08, 2023